First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations – The ASCO Post
- First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations The ASCO Post
- Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer The Manila Times
- Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer Medical Xpress
- ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype Fierce Pharma
- ASCO: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer EurekAlert!
0
Views